Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBerate-OLE long-term extension study of lerodalcibep
2020-004394-49Phase 3Active
- Sponsor
- LIB Therapeutics, LLC
- Start
- May 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lerodalcibep in familial hypercholesterolemia (FH) and hypercholesterolemia, sponsored by LIB Therapeutics, LLC. Primary endpoints: Long-term safety, Long-term tolerability and 1 more. Started May 2021; status: active.
02
Drugs
lerodalcibep
03
Conditions
familial hypercholesterolemia (FH)hypercholesterolemia
Beyond the preview
Go deeper on 2020-004394-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004394-49.